Oral Answers to Questions

Karl Turner Excerpts

Tuesday 19th November 2024 Commons Chamber

[Wes Streeting]

That would be a matter for the right hon. Gentleman’s ICB. I know that he is new to the area, so I am happy to make some introductions.

[Karl Turner (Kingston upon Hull East) (Lab)]

My constituent Craig Eskrett was diagnosed with motor neurone disease 12 months ago. He says that the services are there in the local NHS trust, but there is a distinct lack of co-ordination. Will the Minister meet me to discuss what improvements can be made to co-ordinate those services for sufferers of MND?

[Andrew Gwynne]

My hon. Friend raises a real issue about how we join up the whole of the patient journey. Once diagnosed, patients need appropriate treatment and wraparound care. I am more than happy to meet him and his constituent.

National Insurance Contributions: Healthcare

Karl Turner Excerpts

Thursday 14th November 2024 Commons Chamber

[Karin Smyth]

The SNP has been in charge in Scotland for something like 20 years now—I forget exactly how long, but it seems like a very long time. Again, the Scottish people gave us an excellent result at the general election, and I am delighted to have so many Scottish colleagues here with me now. However, the SNP has the opportunity to make decisions in Scotland around health and social care as well, so I suggest that they do a better job.

[Karl Turner (Kingston upon Hull East) (Lab)]

It is disappointing to put it mildly that the Opposition spokesperson was unable to mention the record funding committed in the Budget.

[Dr Luke Evans]

It was in my opening line—

[Mr Speaker]

Order! The shadow Minister has been granted an urgent question. He asks the questions; he does not answer them from the Front Bench.

[Karl Turner]

Does the Minister agree that it is also disappointing that the Opposition ignore the fact that they completely disregarded and ignored social care when they were in office?

[Mr Speaker]

The Government have no responsibility for that.

Oral Answers to Questions

Karl Turner Excerpts

Tuesday 15th October 2024 Commons Chamber

[Andrew Gwynne]

My hon. Friend makes a really important point. The wonderful staff we have working across health and care ensure that our constituents receive, within a very tightly constrained health service, the best possible care that we can give them. The NHS is broken. We have to fix our broken health service, and having good-quality staff at the heart of it is how we are going to achieve that aim.

[Karl Turner (Kingston upon Hull East) (Lab)]

5. What assessment his Department has made of the adequacy of patient waiting times.

[The Secretary of State for Health and Social Care (Wes Streeting)]

Waiting times are wholly inadequate in our country. That is because the previous Conservative Government took a golden inheritance of the shortest waiting times and the highest patient satisfaction in history and left behind the worst crisis in the NHS’s history. What is more, they accept no responsibility and cannot even bring themselves to say sorry.

[Karl Turner]

I pay tribute to my own family GP, Dr Islam at the East Hull family practice, who goes above and beyond for his patients. However, I know that GPs are troubled by the amount of time patients have to wait to see them. The disparity between GP numbers in different areas is utterly shocking. In Kingston upon Thames, for example, a GP looks after 1,800 patients, but in Kingston upon Hull it is more than double that number. What is my right hon. Friend doing to sort out the Tory mess of the last 14 years?

[Wes Streeting]

May I first, through my hon. Friend, say thank you to Dr Islam and to GPs right across the country who, against the backdrop of the extraordinary challenges they are working through, have none the less managed to deliver more appointments now than when there were thousands more GPs? My hon. Friend is right to point out that we do not have enough GPs in this country. That is why, within weeks of taking office, this Government found just shy of £100 million to put into the frontline to employ 1,000 more GPs who will be seeing patients before the end of this financial year. That will make a real difference, and the shadow Secretary of State should have the humility and to grace accept that.

Motor Neurone Disease Research: Government Funding

Karl Turner Excerpts

Tuesday 13th December 2022 Westminster Hall

[David Mundell (in the Chair)]

I will call Karl Turner to move the motion, and then call the Minister to respond to what is a timely debate following the sad death of Doddie Weir, who through his My Name’5 Doddie foundation was such a great campaigner on the issue. There will be no opportunity for the Member in charge to make a winding-up speech, as is the convention for 30-minute debates.

[Karl Turner (Kingston upon Hull East) (Lab)]

I beg to move,

That this House has considered Government funding for research into motor neurone disease.

It is an absolute pleasure to serve under your chairship, Mr Mundell. MND is a devastating, debilitating and untimely life-limiting disease. We saw that just two weeks ago with the tragic loss of Doddie Weir, to which you have referred. Doddie was a giant of a man, both on and off the field, but the MND Association estimates that in the UK six people a day die of MND. A third of them die within 12 months of diagnosis, but it is now more than a year since the Government pledged—in response to the tireless efforts of campaigners and following meetings between me and the then Business Secretary, the right hon. Member for Spelthorne (Kwasi Kwarteng)—to invest £50 million. We met the Secretary of State that day with campaigners, and he gave an assurance to us all that immediate action, meaning immediate money, would be forthcoming. It was not.

[Jim Shannon (Strangford) (DUP)]

I thank the hon. Gentleman for bringing forward this important issue. I have a close working relationship with MND campaigners back home, and ahead of the debate they got in touch to point out the lack of adequate care and provision in Northern Ireland. The Department of Health back home needs help to improve the standard for accessing clinical trials, and the same applies for people across the UK. Does the hon. Gentleman agree that it is imperative that people in all parts of this great United Kingdom of Great Britain and Northern Ireland are able to gain from research and be involved in clinical trials? We all stand to gain from that.

[Karl Turner]

I agree with the hon. Gentleman, who is an incredibly impressive campaigner on the issue. I pay tribute to him. He is knowledgeable on the subject, and he raises it both publicly in debate and privately with Ministers when given the opportunity. I commend him for that.

I very much welcome the Secretary of State for Health and Social Care commenting at the weekend that the money will be fast-tracked into the hands of researchers, but I am sorry to say that it feels as though the Government have dragged their feet. They have been dragged kicking and screaming to this point by the impressive dedication of MND campaigners—not least Rob Burrow, who is a rugby league legend—and it is disappointing that we have had to wait 12 months for anything. This debate was secured, then there was talk in the media that there would be funding available, but campaigners are entitled to be a little concerned and a little nervous about where and when that money will be forthcoming.

I pay tribute to the campaigners. I have briefly mentioned Rob Burrow; for all his brilliance on the pitch, the whole rugby league community has been blown away by his determination to raise awareness of MND. It is his tenacity that has brought us to where we are today. I have to be honest that I knew very little about MND. I am a rugby league fanatic; I support both of the rugby league teams in Hull. I am bound to say, being the Member for east Hull, that I support the red and whites a bit more than the black and whites on occasion. Rob is the person who brought this to my attention. Special mention should also be given to Rob’s former teammate and best pal, Kevin Sinfield, who has completed seven ultra-marathons in seven days to raise about £1.5 million for MND charities. That is an incredible effort from an incredible campaigner and man.

This debate was secured before the Secretary of State announced the money at the weekend. I want to mention that I have spoken with the MND Association at length, and my office has spoken with it in preparation for this debate. It has one single ask. It desperately needs a meeting with the Secretary of State for Health and Social Care and the Secretary of State for BEIS, so that it can get a timeline and some understanding of when the money will be made physically available. It is no good promising money and then not delivering it. The promise was made more than 12 months ago—nothing has been forthcoming.

I am quite annoyed at the fact that the debate was secured, and all of a sudden there is discussion in the media that the money is coming. People are asking me whether it means 50 million quid last year and 50 million again this year. The reality is that it is 50 million quid, which is much needed—the association and campaigners are grateful for it—but they need to know when and how the money is going to be made available.

I am going to rest there; I do not think I have anything further to add. It is a simple ask: will the Minister agree to speak to the Secretaries of State concerned and put the meeting together as quickly as possible, so that we can move forward?

--- Later in debate ---

[Helen Whately]

It is good to hear from my hon. Friend. Credit goes to him for his campaigning, both personally and as chair of the APPG on motor neurone disease, together with that of other Members of Parliament, to push for investment to get out to the frontline on research. I look forward to working with him further so we can ensure this investment in research makes a difference for people suffering from MND and their carers, and for those in the future.

I have just mentioned the MND collaborative partnership, which is a mechanism by which the many initiatives that I just described will come together. The first meeting of this virtual institute took place at the end of November, and I am looking forward to hearing about further progress now that the funding is in place. The remainder of the committed £50 million of MND funding is available for researchers to access via the NIHR and the Medical Research Council. Government will support researchers in coming forward with ideas for new research via a joint highlight notice between NIHR and the Medical Research Council on MND. That will allow our funding to be responsive to progress in science and ensure breakthroughs reach patients in the quickest possible time. Further to that, the Secretary of State will shortly host leading researchers and patient groups at a roundtable to discuss MND research and help researchers make the best bids as quickly as possible. That addresses the call for a meeting from the hon. Member for Kingston upon Hull East.

[Karl Turner]

I am grateful to the Minister and I welcome everything that she has helpfully just announced. However, my researcher spoke yesterday to the association and it still requests that meeting. It is the only ask. I accept what she says about roundtables and all sorts of other things going on behind the scenes, but the association wants a meeting with the Secretary of State for Health and Social Care and the Secretary of State for Business, Energy and Industrial Strategy. Perhaps it is difficult to get them together, so there could be separate meetings. That is the only thing the association has asked me to ask for today, so it would be remiss of me if I did not push her to request that meeting after she leaves here.

[Helen Whately]

The hon. Member’s request is very clear. As I said to him a moment ago, the Secretary of State for Health and Social Care will meet researchers and patient groups at a roundtable about this issue. If that is not the same meeting as the one he wants, I am very happy to take that point away and find out exactly what meeting he wants and how we can make sure that it takes place as well as the planned meeting.

I have heard from my hon. Friend the Member for Northampton South over the past few weeks about red tape getting in the way of research, which we clearly do not want to be the case. To help cut red tape, research funders from NIHR and the Medical Research Council are working together so that MND proposals will go to the right scheme at the early idea stage and so that applications can be considered before they even have full sign-off from their universities and institutions.

We are also building on our recent announcement of £790 million for the NIHR biomedical research centres by putting in MND funding, so that it gets quickly to the most promising researchers already working on MND.

To sum up and return to where we started, there is no doubt that MND is a cruel disease that takes people before their time and, as it does so, takes them bit by bit from their loved ones. As yet, there is no cure. However, I say “as yet” because I have hope, and we have real grounds for optimism with the clinical trials. We also have £50 million going into MND research. I have outlined today how we are accelerating that funding to go to the frontline of research and to develop the treatments that will make a difference to MND sufferers, whether here and now or in the future.

In no small part, that is thanks to the late Doddie Weir and his family, Rob Burrows, Ed Slater, Kevin Sinfield, and all the other MND campaigners and carers who have worked so hard to raise awareness of MND and push for more action on MND research. I can assure them that their efforts are not in vain. I personally take inspiration from all their tireless work, which reinforces the Government’s commitment to fund and support research into MND. We owe it to people with MND, future sufferers, and all the campaigners and researchers to push ahead with the groundbreaking research that will help to develop effective treatments and, indeed, cures for this cruel disease.

Question put and agreed to.

NHS Industrial Action: Government Preparations

Karl Turner Excerpts

Monday 12th December 2022 Commons Chamber

[Will Quince]

I thank my right hon. Friend for that question. I am sometimes staggered by the number of people on six-figure salaries within our NHS, but in an organisation of its size, management is also important. It is about getting the balance right, but we always continue—[Interruption.] The hon. Member for Ilford North (Wes Streeting) chunters from a sedentary position. The balance may not be right, and we always continue to look at the ratio of management to frontline staff to make sure we are getting that right.

[Karl Turner (Kingston upon Hull East) (Lab)]

The Government will blame anybody and everybody for these avoidable strikes, but he knows full well that the RCN is not even affiliated to the TUC, let alone the Labour party. If these strikes go ahead, the Secretary of State is to blame, because he has the power to sort out this mess. Why does he not just get on with it?

[Will Quince]

The hon. Gentleman puts it in his usual blunt way. The pay review body process is the established mechanism for determining pay uplifts in the public sector, outside of negotiating multi-year pay and contract reform deals. Despite what he says, industrial action is a matter for the unions, and we urge them to carefully consider the potential impacts of industrial action. The Secretary of State and I have been clear that our door is open. We have already met with the unions, and we would be happy to do so again.

Oral Answers to Questions

Karl Turner Excerpts

Tuesday 6th December 2022 Commons Chamber

[Neil O’Brien]

That is something that we are working on very actively. As well as financially supporting GPs to roll out new and better ways of managing their appointments, we are looking at what criteria we expect from GPs. We already set out some moves in our summer action plan, but we will be looking further at preventing the lamentable situation my hon. Friend describes of people being asked to ring back or being held in long phone queues. That is not acceptable.

[Karl Turner (Kingston upon Hull East) (Lab)]

T3.   The public are not daft. They know that the backlogs in the NHS existed well before the pandemic, they know that the NHS was already on its knees, and they know that it was this Tory Government who brought it to its knees. So why do the Government not take up Labour’s policy of scrapping non-dom status, use the £3.6 billion to train nurses, doctors and midwives, and get the NHS back on its feet? People in east Hull want nurses, not non-doms.

[Steve Barclay]

The data is very clear; in fact, it is very stark on the extent to which the backlog is driven predominantly by the pandemic. That is why we have a programme, through the extra investment in the autumn statement: the £6.6 billion over the next two years going into the NHS, but also the £2.8 billion next year and £4.7 billion the year after into social care, and £8 billion in 2024. We recognise the size of those backlogs, so we can fund the surgical hubs and diagnostic centres.

Government PPE Contracts

Karl Turner Excerpts

Tuesday 6th December 2022 Commons Chamber

[Will Quince]

I will come on to many of the points the hon. Gentleman has raised, but I will just say this about UK supply chains. At the beginning of the pandemic, only 1% of PPE used in the UK was produced here. At present, three quarters of the FFP-3 masks provided to the NHS and social care are now manufactured in the United Kingdom and contracts were signed with around 30 UK-based companies to manufacture around 3.9 billion items of PPE.

Colleagues will recall those early days, with planes being turned around on the tarmac, countries imposing export bans, huge inflation in global prices and the price of crucial items such as glass increasing sixfold. These were the conditions under which tough decisions were taken, and these were the decisions under which PPE was procured. These were the conditions under which we stepped up to protect our most vulnerable and to save lives.

[Karl Turner (Kingston upon Hull East) (Lab)]

How can the Minister possibly square the fact that Arco, a leading clinical PPE supplier to the NHS since its inception —the company has existed in Hull for more than 100 years—did not get a sniff of a contract from the Department of Health and Social Care because it was nowhere near a VIP lane? He should be saying sorry from the Dispatch Box, not all this nonsense. Just ‘fess up and say sorry.

[Will Quince]

There were lots of words there, and lots of aggression. [Interruption.] Let us be frank, there was.

I will address many of those points. I fear the hon. Gentleman forgets the pressure under which civil servants were working at the time and the pace at which decisions had to be taken. [Interruption.] If he would like to write to me with those exact conditions—

[Karl Turner]

rose—

[Madam Deputy Speaker (Dame Rosie Winterton)]

Order. The hon. Gentleman must allow the Minister to answer. It is not fair to shout back as soon as he starts answering.

--- Later in debate ---

[Will Quince]

I have given way to the hon. Lady once already, as I promised I would, and I have been generous with my time, so I will not give way again.

[Karl Turner]

rose—

[Will Quince]

I also gave way to the hon. Gentleman, so let us leave it.

We should be proud of the remarkable progress we have made on PPE. We are now confident that we have enough stock to cover all future demands arising from covid-19. The right hon. Member for Ashton-under-Lyne mentioned some figures in relation to storage costs, and I am pleased to say that those are now significantly reduced—I will write to her about the cost of storing that PPE here in the UK.

Moreover, we have strengthened our country’s PPE supply chain for the long term, including manufacturing more PPE here in the UK. Before the pandemic, as I said at the beginning of my speech, just 1% of our PPE was produced here. Now the Government have awarded contracts to around 30 manufacturers for the supply of almost 4 billion items of PPE.

We have learned many lessons from this pandemic, and when it comes to PPE we are on a stronger footing today than ever before, but the successes of our enormous national effort at a time of unprecedented national crisis deserve to be recognised. People from all walks of life came together to protect people in the NHS and social care, and in doing so they saved lives. Even as we continue to learn and to build a system fit for the future, this Government will remain enormously proud of everything that was achieved.

Oral Answers to Questions

Karl Turner Excerpts

Tuesday 1st March 2022 Commons Chamber

[Gillian Keegan]

The National Institute for Health Research welcomes funding applications for research into any aspect of human health, including epilepsy, and we would welcome those pharmaceutical companies coming forward to partake in trials. The NIHR and the NHS will support a programme of two randomised control trials into epilepsy, which will compare medicines containing cannabidiol, and CBD plus tetrahydrocannabinol and a placebo. This is a pioneering area of research, and I am aware that NHS England and NIHR are working closely to get those trials started as soon as possible.

[Karl Turner (Kingston upon Hull East) (Lab)]

12. What steps his Department is taking to tackle regional health inequalities including waiting times for NHS treatment.

[The Parliamentary Under-Secretary of State for Health and Social Care (Maria Caulfield)]

We are determined to address the many health disparities that exist across England, particularly in areas such as maternity. Last week I was pleased to announce the maternity disparities taskforce. It aims to tackle the difference in outcomes for pregnant women based on their race and background, which we want to end.

[Karl Turner]

The problem is that the Government talk a good scrap, but their record on health inequalities is utterly deplorable. Before the pandemic, 4.5 million people were waiting for treatment on NHS lists, and 5,000 people in Hull were waiting for treatment at Hull Royal Infirmary and Castle Hill. Why is someone who lives in east Hull more than twice as likely to be waiting for more than 12 months on an NHS waiting list?

[Maria Caulfield]

While I recognise that the waiting times in Hull are some of the highest in the country, I am sure the hon. Gentleman will welcome the investment that the Government are putting into his constituency to change that. The Royal Infirmary and Castle Hill Hospitals have £60 million of funding, and his own hospital recognises that it will provide some of the most modern facilities in the country. That includes £2.8 million for new respiratory wards, £1.6 million for new specialist theatre facilities, and £1.1 million for oxygen resilience wards, ensuring that his local hospital is able to tackle some of those health disparities.

Covid-19 Update

Karl Turner Excerpts

Monday 6th December 2021 Commons Chamber

[Sajid Javid]

Departments across Government work together on the pandemic, and that means that my Department works very closely with the Department for Transport.

[Karl Turner (Kingston upon Hull East) (Lab)]

Not all, but most Members of this House and the general public would support the Secretary of State when he says that he has to impose further curbs on people’s freedoms, but does he not accept that people would perhaps be a bit more enthusiastic if when he comes back to the Dispatch Box, he fesses up, accepts that there was a knees-up in No. 10 last year when people were dying without family members there present with them, and apologises on behalf of the Prime Minister?

[Sajid Javid]

I thought it was going to be a serious question.

Randox Covid Contracts

Karl Turner Excerpts

Wednesday 17th November 2021 Commons Chamber

[Gillian Keegan]

I will give way to hon. Members, but if they want to hear some of the facts, of which I have lots, I am happy to get on with my speech. I will give way to the hon. Member for Kingston upon Hull East (Karl Turner) on this occasion.

[Karl Turner (Kingston upon Hull East) (Lab)]

I am grateful to the Minister for giving way. She has been given a terribly tough gig, but she does not seem to be answering the point made a little earlier. Arco in Hull had existed for 135 years and had supplied the NHS with top-quality products since its very inception. It was blocked from the VIP lane—why?

[Gillian Keegan]

As I said, I would like to get on to answering some of these questions, so if Members will bear with me and let me get my speech out, I will have time to answer further interventions.

The context in which we were operating was the fear that we would run out of vital testing equipment, that we would not have the capacity to test people for covid and that, as a result, this deadly virus would continue to pass from person to person, overwhelm our national health service and cause untold devastation. It is the duty of any responsible Government to do all they can to prevent such a grim outcome, to save lives, to protect our key workers and to partner with as many people as are available with the experience and expertise to get things done. So we engaged with many thousands of businesses, large and small, from all over the country and all around the world, to set out what we needed and find out what they could do.

Randox has been globally recognised in the in vitro diagnostics industry for nearly 40 years. It is a British business with roots in Northern Ireland and a history of developing diagnostics solutions for hospitals, clinical settings and research labs. Even as early as March 2020, Randox had lab-based polymerase chain reaction testing capacity for covid-19. Against the fears that we would not have enough testing capacity, we worked with companies with existing diagnostic capability—that is just plain common sense.

--- Later in debate ---

[Anneliese Dodds]

The Minister is obviously doing her very best, but yet again, I am afraid that this is not an edifying spectacle. In the overwhelming majority of cases, the recommendation led to companies receiving enormously expensive contracts. It is risible to suggest anything less. It is also risible to suggest that in those cases the Government followed their own emergency procurement guidance:

“Contracting authorities should maintain documentation on how they have considered and managed potential conflicts of interest in the procurement process…Particular attention should be taken to ensure…decisions are being made on the basis of relevant considerations and”—

wait for it—

“not personal recommendations.”

There was nothing inevitable about this. I know how things ran in Labour-run Wales, and they did not run like this.

We have seen that companies with links to the Conservative party were 10 times more likely to secure a contract than others. Public money was doled out based not on a company’s abilities but on its contacts book. When it comes to spending taxpayers’ money on testing and PPE equipment that can save lives, one would hope that the Government would take things more seriously, but as my hon. Friend the Member for Wallasey (Dame Angela Eagle) said, the switch into an emergency process provides no justification for the ransacking of public money we have seen. As the hon. Member for Amber Valley said, an emergency situation was not a reason for having no process at all. In practice, there should have been more sensitivity around the process, not less.

Because of the Government’s approach, British businesses that did not have Tory MPs on speed dial missed out.

[Karl Turner]

I know that the Minister has not managed to answer the question that I posed earlier, but Arco, in the city of Hull, had existed for 135 years, had provided top-quality products to the NHS since its very inception, and could not get on the VIP lane. Why was it blocked?

[Anneliese Dodds]

My hon. Friend is absolutely right. Earlier in the debate, he detailed that sorry tale in devastating manner, as did my hon. Friend the Member for Kingston upon Hull West and Hessle (Emma Hardy). Arco had existed for 135 years, providing essential material. It was completely ignored, yet Ayanda Capital, for example—an investment firm with no PPE experience —ended up being used by the Government to purchase 50 million masks that were not even usable.

There were other companies that missed out. Multibrands International, based in Bradford, had been providing PPE to the Chinese Government since the end of 2019. It spent months trying to offer those services to the UK Government, but got absolutely nowhere. What did the Government do instead? They bought 400,000 protective gowns from Turkey that were unusable.

That is the way it always seems to be with the Conservative party: one rule for the Conservatives and their friends, another rule for everyone else—and it is the British people who pay the price. This Conservative Government are doing their best to suggest that every politician was engaged in graft. They are trying to drag everyone else down to their level and feed a growing disillusionment with our politics that damages us all. But Labour Members know that that is not true; I suspect that a fair few Conservative Members know it, too.

The people of Britain know when they are being taken for fools. When a party found guilty of breaking the rules tries to remake them to protect one of its own, there is a word for that: corruption. That is what this Prime Minister has brought into the heart of our politics, and the British people will not tolerate it. That is why the Prime Minister panicked last week and U-turned: because he knew that he had been rumbled.

We all have to play by the same rules, whatever the Prime Minister thinks. Labour has been clear that if we were in power, things would change. We would ban dodgy second jobs like those of the former Member for North Shropshire—and I mean a proper ban, not the watered-down cop-out that the Prime Minister is trying to lay down this afternoon. We would close the revolving door and ban Ministers from lobbying for at least five years after they leave office. We would stop Conservative plans to allow foreign money to flow into our politics, and ban the use of shell companies to hide the source of donations. We would create a new office for value for money and reform procurement rules to put an end to the industrial-scale wasting of public money, and we would create a new, genuinely independent integrity and ethics commission to restore the standards in public life that have been trashed by this Government.

This scandal has presented a clear choice about the kind of politics we want for our country. Do we want Boris Johnson’s politics of the gutter, or Keir Starmer’s politics of decency and integrity? Conservative Members have a choice today as well. They can abstain, under orders from the Prime Minister, their Chief Whip and the Leader of the House; or they can decide to make a stand. They can decide that they want to have a vote on this because they want to take a better path. Let us be very clear about the message that abstention is going to send. We have heard weasel words during this debate, and it seems clear that the scope of what the Government are proposing today, in terms of what they are willing to release, is far less than what Labour’s motion requires.

I see the Minister shaking her head. I sincerely hope that she has got that correct, because, having listened to what she said and compared it with what is written in the Labour motion, I think that there is far less that this Government are prepared to reveal.

--- Later in debate ---

[The Parliamentary Under-Secretary of State for Health and Social Care (Maggie Throup)]

I am pleased to be able to close this debate on behalf of the Government. As my hon. Friend the Minister for Care and Mental Health said earlier, the Government are not intending to vote against the Humble Address. We will review what information we hold in scope, come back to Parliament and deposit it in the Library of the House, which is in line with the Government’s established stance on responding to Humble Addresses.

I am, however, grateful for the opportunity that we have had to address the important issues raised today: questions of how, as a country, we can rise and meet the challenges that we face, how we can ensure we have a system that is not only fast but fair, and how we can learn lessons from this most challenging period in our history. One of the most important lessons I take from it is that when we work together, we can do incredible things. We can build a testing capacity almost from scratch, we can reach millions of people in a single day, and we can save lives on a massive scale. Imagine what would have happened had we not worked with so many incredible partners to deliver these efforts—because no one can do it on their own, especially in such unprecedented circumstances, so it is the duty of a responsible Government to work with anyone who can deliver. The NHS has been phenomenal, our hospitals have been phenomenal and local government has have been phenomenal, but so have those in the private sector. We could not have come this far without them.

When we look at the situation today, it is easy to forget just how far we have come.

Back in March 2020, we could process just a few thousands of tests in a day; now we can process millions. That we have achieved this is no accident. In respect of developments from testing kits to processing, logistics to lateral flow devices, those partnerships between the NHS, industry, academia, local government and so many others have made the difference—and contracts with companies such as Randox have been some of the essential building blocks without which we would never have built what is now one of the largest testing networks in the world.

Randox laboratories have carried out over 15 million tests for covid-19. More than 730,000 positive cases have been identified under Randox contracts, which meant that those people could self-isolate, protect others, and help to bring the pandemic under control. An independent assessment gave a positive assessment of Randox’s performance. It exceeded their contract targets, hitting 120,000 tests in a single day in March 2021.

[Karl Turner]

Would the Minister like to comment on the fact that 750,000 testing kits that were put into care homes were no good at all? What has she to say about that?

[Maggie Throup]

In a statement on 18 July 2020, the Secretary of State informed the House that a batch of swab test kits were not up to the usual high standard. As a precautionary measure, they were withdrawn, and replacement kits were supplied as soon as possible.

--- Later in debate ---

[Maggie Throup]

Obviously those details were in the contracts, but I am sure that they conformed with the key performance indicators.

All the contract award notices can be seen on Contracts Finder. We have nothing to hide, Madam Deputy Speaker —nothing at all. The House, and the public, can see what taxpayers’ money has been spent on. We have applied exactly the same criteria, standards and processes in the case of Randox as we have in all other cases. Randox has never been an exception, and we utterly reject the idea that it has received any kind of special treatment. Our partnership with Randox is simply a reflection of the situation in which we found ourselves in March 2020, facing a global pandemic of unknown and unprecedented proportions and acting as a responsible Government should. We worked against genuine fears that we would run out of vital testing equipment, that we would not have the capacity to test people and that the deadly virus might continue to spread from person to person, silent and undetected.

We engaged with Randox and many others. Not only was Randox a UK-based business, but its early laboratory-based PCR testing capacity for covid-19 was capacity that we have been able to use for the whole of the UK. We have fought this pandemic as one United Kingdom. Working with Randox was the right thing to do, it was the responsible thing to do and, quite simply, it was a decision that has saved many thousands of lives.

I will address one issue brought up by a couple of Opposition Members, and reassure them that Arco was awarded contracts for PPE. I thank Arco for its contribution in providing life-saving PPE that we needed at that time.

[Karl Turner]

The reality is that Arco went directly to various NHS branches to offer its services to supply. It was blocked from any formal route. It was not on the VIP list. That is the reality.

[Maggie Throup]

I reiterate that Arco was awarded contracts for PPE.

Of course, that does not mean there are no lessons to be learned, and I can reassure the hon. Member for Blackburn (Kate Hollern) that the public inquiry will be an important learning moment for us all. We are already making changes: we published our procurement Green Paper last December, we updated our commercial guidance on the management of actual and perceived conflicts of interest in May, and we are implementing the recommendations from the first and second Boardman reviews into improving procurement.

The real lessons, however, are just what we can achieve when we all get behind a shared mission, to protect the British people and to protect the NHS. That is a mission-driven way of working that has seen us work beyond the traditional boundaries and achieve remarkable results. We have tested millions of people for covid-19 and kept millions more safe. I am very proud of that, and so too, I believe, are the British people.

Question put and agreed to.

Resolved,

That an Humble Address be presented to Her Majesty, that she will be graciously pleased to give directions that there be laid before this House the minutes from or any notes of the meeting of 9 April 2020 between Lord Bethell, Owen Paterson and Randox representatives, and all correspondence, including submissions and electronic communications, addressed or copied to, or written by or on behalf of, any or all of the following:

(a) a Minister or former Minister of the Crown,

(b) a Special Adviser of such a Minister or former Minister, or

(c) a Member or former Member of this House

relating to the Government contracts for services provided by medical laboratories, awarded to Randox Laboratories Ltd. by the Department for Health and Social Care, reference tender_237869/856165 and CF-0053400D0O000000rwimUAA1, valued at £133,000,000 and £334,300,000-£346,500,000 respectively.

Royal Assent